Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
BLRX Bioline Rx Ltd
- Stocks
- Healthcare
- NASDAQ: BLRX
Price (delayed)
$4.67
Market cap
$20.85M
P/E Ratio
N/A
Dividend/share
N/A
EPS
$0
Enterprise value
$8.23M
biolinerx is a clinical-stage, publicly-traded (nasdaq/ tase: blrx) biopharmaceutical development company based in modi'in, israel. this website or social media page (the “site”) of biolinerx ltd. (the “company”) may contain
Highlights
Bioline Rx's quick ratio has surged by 102% YoY and by 32% QoQ
BLRX's EPS has surged by 100% since the previous quarter and by 100% year-on-year
The company's gross profit has surged by 123% YoY but it fell by 26% QoQ
The revenue has soared by 92% YoY but it has contracted by 23% from the previous quarter
Key stats
What are the main financial stats of BLRX
Market
Valuations
Earnings
Shares outstanding
4.47M
Market cap
$20.85M
Enterprise value
$8.23M
Price to earnings (P/E)
N/A
Price to book (P/B)
1
Price to sales (P/S)
0.93
EV/EBIT
1.58
EV/EBITDA
0.96
EV/Sales
0.37
Revenue
$22.34M
Gross profit
$14.5M
Operating income
-$17.98M
Net income
-$3.4M
EBIT
$5.21M
EBITDA
$8.55M
Free cash flow
-$32.38M
Per share
Balance sheet
Liquidity
EPS
$0
EPS diluted
$0
Free cash flow per share
-$7.3
Book value per share
$4.67
Revenue per share
$5.04
TBVPS
$7.46
Total assets
$43.51M
Total liabilities
$22.65M
Debt
$13.74M
Equity
$20.86M
Working capital
$17.89M
Debt to equity
0.66
Current ratio
2.27
Quick ratio
2.02
Net debt/EBITDA
-1.48
Margins
Efficiency
Dividend
EBITDA margin
38.2%
Gross margin
64.9%
Net margin
-15.2%
Operating margin
-80.5%
Return on assets
-6.8%
Return on equity
-23.9%
Return on invested capital
50.2%
Return on capital employed
17.7%
Return on sales
23.3%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
BLRX stock price
How has the Bioline Rx stock price performed over time
Intraday
-0.43%
1 week
-21.25%
1 month
44.14%
1 year
-82.52%
YTD
-45.44%
QTD
57.77%
Financial performance
How have Bioline Rx's revenue and profit performed over time
Revenue
$22.34M
Gross profit
$14.5M
Operating income
-$17.98M
Net income
-$3.4M
Gross margin
64.9%
Net margin
-15.2%
The company's gross profit has surged by 123% YoY but it fell by 26% QoQ
The net margin has surged by 96% year-on-year and by 52% since the previous quarter
BLRX's net income has soared by 93% YoY and by 63% QoQ
The revenue has soared by 92% YoY but it has contracted by 23% from the previous quarter
Price vs fundamentals
How does BLRX's price correlate with its fundamentals
Growth
What is Bioline Rx's growth rate over time
Valuation
What is Bioline Rx stock price valuation
P/E
N/A
P/B
1
P/S
0.93
EV/EBIT
1.58
EV/EBITDA
0.96
EV/Sales
0.37
BLRX's EPS has surged by 100% since the previous quarter and by 100% year-on-year
The stock's price to book (P/B) is 68% less than its 5-year quarterly average of 3.1 and 66% less than its last 4 quarters average of 2.9
The equity has soared by 60% YoY and by 55% from the previous quarter
The revenue has soared by 92% YoY but it has contracted by 23% from the previous quarter
BLRX's P/S is 45% below its last 4 quarters average of 1.7
Efficiency
How efficient is Bioline Rx business performance
BLRX's return on sales has surged by 106% year-on-year
Bioline Rx's return on equity has surged by 93% YoY and by 68% QoQ
BLRX's return on assets has surged by 92% year-on-year and by 62% since the previous quarter
Dividends
What is BLRX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for BLRX.
Financial health
How did Bioline Rx financials performed over time
The company's total assets is 92% higher than its total liabilities
Bioline Rx's quick ratio has surged by 102% YoY and by 32% QoQ
The company's current ratio has surged by 99% YoY and by 29% QoQ
The debt is 34% smaller than the equity
The equity has soared by 60% YoY and by 55% from the previous quarter
The debt to equity has contracted by 41% from the previous quarter and by 24% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.